The near-term test is whether reform meets the review's originally stated objective of modernising and accelerating access to new medicines and other health technologies. That outcome cannot be separated from the institutional response. Can any beneficial reforms hold? The United Kingdom offers a timely example of the risks. …
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit -
Taking a stake is not the same as spectating investor risk and expecting a benefit
September 10, 2026 - - Latest News -
Melbourne oncologist takes the reins at Australia's private cancer physicians body
September 10, 2026 - -
Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this
September 10, 2026 - - Latest News